Meiyu Wu
139 Renmin Rd
Changsha, 410011, China
Changsha, 410011, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Resmetirom for noncirrhotic metabolic dysfunction-associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: August 12, 2026
Cost-Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective.
Journal: Hematological oncology
Published: April 25, 2026
First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis.
Journal: Immunotherapy
Published: April 25, 2026
Cost-effectiveness of targeted therapy versus chemotherapy for patients with advanced or metastatic gastric cancer in China.
Journal: Frontiers in pharmacology
Published: March 26, 2026
The economic burden of depression disease for China, India and the USA in 2025-2050: a health-augmented macroeconomic modelling study.
Journal: BMC medicine
Published: February 16, 2026
Pharmacoeconomic evaluation of weight-based vs fixed-dose pembrolizumab for non-small cell lung cancer in China.
Journal: Frontiers in immunology
Published: July 14, 2025
Economic evaluation of Erdafitinib as a second-line treatment for advanced metastatic urothelial carcinoma: real-world data from the USA and prospective analysis from China.
Journal: Future oncology (London, England)
Published: May 10, 2025
Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: January 09, 2025
Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: August 31, 2024
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.
Journal: Clinical and molecular hepatology
Published: August 13, 2024
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.
Journal: Frontiers in immunology
Published: July 13, 2024
Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: July 10, 2024
Last Updated: 09/26/2026